Kyowa Kirin's lead biologic enters the clinic for new asthma indication
This article was originally published in Scrip
Japan's Kyowa Hakko Kirin has unveiled a further broadening of potential indications for its lead therapeutic biologic mogamulizumab (KW-0761), disclosing in its first quarter results that it has started a Japanese clinical development programme for asthma.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.